Scientists at the University of Birmingham have revealed the roles that different types of gene mutations play in causing blood cancers in a study that was the culmination of a decade's research.
The effort, called PROPEL (Public Resource of Patient-derived and Expanded Leukemias), aims to advance fundamental research on the biology of leukemia and to help develop cures by sharing unique patient-derived xenograft samples with researchers around the world. PROPEL samples are available free of charge to researchers with no obligation to collaborate.
If data is a key weapon in the global war against cancer, then a recent data release for researchers - funded by Bala Cynwyd-based nonprofit Alex's Lemonade Stand Foundation - could be D-Day for pediatric cancer. To the tune of $550,000, the nonprofit funded the release of genomic data on 270 cancer tumors.
For the first time, researchers have discovered a link between a pathway that activates a protein called HSF1 and leukemia. Blocking just a single gene in this pathway with a drug now in development for breast cancer could offer a new way of treating an aggressive form of leukemia, they believe.
For the estimated 600 children who battle terminal leukemia each year in the United States, there is new hope. And in the fledgling field of T-cell immune therapies, there is new excitement. In a resounding vote of confidence for a first-of-its-kind cancer treatment, a U.S.
“We believe that when this treatment is approved it will save thousands of children’s lives around the world,” Emily’s father, Tom Whitehead, told the panel.
October 21, 2016, by NCI Staff An immunotherapy approach that uses a new method of preparing immune cells may provide a potential treatment option for some patients with acute myeloid leukemia (AML), results from an early-stage clinical trial suggest.
September 30, 2016, by NCI Staff Research from an NCI-funded program studying a group of rare and hard-to-treat childhood cancers has set the stage for two Children’s Oncology Group-led clinical trials that are evaluating new treatment options for children with acute lymphoblastic leukemia (ALL).
May 4, 2016, by NCI Staff The Food and Drug Administration (FDA) approved venetoclax (Venclexta®) on April 11 for patients with chronic lymphocytic leukemia (CLL) whose tumors have a specific genetic alteration.
January 15, 2016, by NCI Staff Reports from two early-stage trials of new oral drugs provide hope for patients with high-risk chronic lymphocytic leukemia (CLL) that has returned after prior treatment. Results from both trials were presented last month at the annual meeting of the American Society of Hematology (ASH) and published in the New England Journal of Medicine ( NEJM).